Karen Wolmarans

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Antonio J. Vallejo‐Vaz, Christophe Stevens, Alexander R.M. Lyons et al. · The Lancet · 2021 · 305 citations · Full text

Public Health, Endocrinology, Genetics +13

Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia

Anouk van der Graaf, Melchior C. Nierman, Jean Firth et al. · Acta Paediatrica · 2006 · 56 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C

Xander M. van Delden, Roeland Huijgen, Karen Wolmarans et al. · Atherosclerosis · 2018 · 14 citations

Life Sciences, Cardiology, Genetics +16